内稳态与病理条件下的铁下垂之路。

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-10-06 eCollection Date: 2021-01-01 DOI:10.1080/23723556.2021.1970477

Vincent Chen, Chu Bo, Wei Gu

引用次数: 2

摘要

钙非依赖性磷脂酶iPLA2β已被确定为肿瘤抑制因子TP53(或p53)的转录靶点。与GPX4(谷胱甘肽过氧化物酶4)不同，iPLA2β不是正常体内平衡所必需的，但在应激反应中对铁凋亡至关重要。我们的研究结果表明iPLA2β在非典型铁死亡途径中是一个重要的调节因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

The roads to ferroptosis under homeostatic versus pathological conditions.

查看原文本刊更多论文

The roads to ferroptosis under homeostatic versus pathological conditions.

The calcium-independent phospholipase iPLA2β has been identified as a transcriptional target of the tumor suppressor TP53 (or p53). Unlike GPX4 (glutathione peroxidase 4), iPLA2β is not required for normal homeostasis but critical for ferroptosis during stress responses. Our results implicate iPLA2β as an essential regulator in a noncanonical ferroptosis pathway.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.